KFA
CRBP icon

Kelleher Financial Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Kelleher Financial Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-383
Closed -$86K – 81
2018
Q3 		$86K Hold
383
– – 0.11% 92
2018
Q2 		$58K Buy
+383
New +$69.6K 0.08% 85

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kelleher Financial Advisors's CRBP Position: Q4 2018 in Review

Kelleher Financial Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q4 2018, closing a stake of 383 shares — an estimated $86K sold.

Kelleher Financial Advisors first reported a position in CRBP in Q2 2018 and held it in 2 quarters. The position peaked at $86K in Q3 2018. 83 funds tracked by Wall St. Rank hold CRBP as of Q4 2018.

  • Kelleher Financial Advisors reported no remaining Corbus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Kelleher Financial Advisors sold 383 Corbus Pharmaceuticals shares in Q4 2018, an estimated $86K.
  • Kelleher Financial Advisors first reported a position in Corbus Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Kelleher Financial Advisors's Corbus Pharmaceuticals position peaked at $86K in Q3 2018.
  • 83 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2018.

Based on Kelleher Financial Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.